Taly is a molecular toxicologist, she obtained her PhD in 2003 from Université Paris Descartes working in the center for molecular genetics (CGM, Gif sur Yvette/ D. Pompon/G. Truan). In 2003, she moved as a post-doc to MRC LMB Cambridge, UK in the framework of an ITN Marie-Curie network. In 2006, she obtained a permanent CNRS position (ISIS, Strasbourg, lab Pr Griffiths). She defended her Habilitation to Direct Research (HDR) in 2008. In 2011, she moved to Paris to establish her own autonomous interdisciplinary group within a high level clinical environment. She is director of research (DR2) since 2015. In total, she supervised29 Master /Bachelor students (2012-17), 11 PhD, 10 post-doc, 1 permanent research engineer, 5 technician or engineers. Her group is actually composed of 15 scientists. She got awarded twice the CNRS award for scientific excellence (2012-15 & 2016-19) and a “Prix équipe à l’honneur” with P. Laurent-Puig. Since 2016 her team is Labelized from the liguecontre le cancer.
She has been involved in the organization of international conferences via participation to advisory panels (>12), technical prog. Committees (3), scientific committee (NanoBio Interfaces in Healthcare and Sciences since 2015) or as organizer (single cell genomics workshop 2017, ICM, Paris). She is often solicited for reviewing of scientific articles or grants both in cancer research and microfluidics. Within others, she is member of the steering committee of the CNRS “GDR micro et nanofluidique”, the interdisciplinary panel of the FWO foundation (Belgium) and nominated member of INSERM CSS6 commission (Technology for health and public health) and FdV doctoral school (ED474). She is part of the founding committee of the DIM ELICIT (2017-2021) of region IdF and« INTERNATIONAL SOCIETY OF LIQUID BIOPSY (ISLB) » (Granada, Spain). She is involved in the Frontiers in Life Science interdisciplinary bachelor since its creation in 2011 (Univ. Paris Descartes) both in student selection and courses coordination. She published 60 publications in peer-reviewed journals including 19 as corresponding author (5 highly cited, Top 1%). Her publications attracted >2250 citations (h-index (ISI): 21, average citation per item: 36). Her work also led to 4 patents and 6 book chapters. She gave 48 invited talks in international conferences and 24 seminars. She co-edited a book with JL Viovy& S Descroix (Springer) and acted as invited editor of Biomolecular Detection and Quantif. journal.
As a molecular toxicologist, she was involved during her PhD in the emerging field of protein directed evolution and its application to the understanding of functional plasticity of cytochromes P450 (CNRS). She became familiar with the development of innovative technologies. In 2003, she moved as a post-doc to MRC Cambridge, UK (ITN network) to develop high-throughput sorting of double-emulsion using FACS for enzyme directed evolution and started to work with droplet-based procedures. In 2006, she obtained a CNRS permanent position to develop microfluidic systems with a focus on directed evolution for biotechnological applications and, starting from 2008, for cancer biomarker identification. In 2011, she moved to Paris to establish a new autonomous interdisciplinary group within a high level clinical environment while maintaining her strong links with the microfluidic community. Her team performs cutting-edge developments in microfluidic systems with direct applications for cancer patients and took a major role in the emergence of the now blooming field of dPCR and liquid biopsy. With P. Laurent-Puig, they were one of the first team to demonstrate that microfluidic droplet-based digital PCR allowed to reach unprecedented sensitivity to detect rare sequences within patient samples. The team thus took a major role in the characterization and understanding of the clinical impact of the presence of rare subclones within colorectal tumors. In parallel, the laboratory also demonstrated the pertinence of both digital PCR and optimized NGS procedures in the emerging field of liquid biopsy. The results were obtained through a large number of retrospective and prospective studies initiated and managed within the laboratory. The team demonstrated that circulating tumor DNA was a strong prognostic and predictive marker in several cancers including colorectal, lung and pancreatic cancers. On going works involves rectal, gastric and ovarian cancers. The team also identified and validated two epigenetic biomarkers allowing perform ctDNA follow up of colorectal cancer patients without knowledge of the tumor genotype. Finally, in strong collaboration with clinicians, innovative microfluidic tools for the characterization and understanding of tumor heterogeneity and evolution were also developed.